The Hindu National
중도 성향
기타
Kia India, RTIH to set up advanced prototyping centre in Amaravati
Facility to support startups, innovators and entrepreneurs with product development, testing and manufacturing infrastructure
"STARTUPS" · 총 51건
필터 보기현재 지수
50.3
0 = 부정 우세
50 = 중립
100 = 긍정 우세
최근 7일 기준 85,043건을 분석한 결과, 뉴스 심리지수는 50.2(균형)입니다. 긍정 4,231건(5.0%)·중립 78,707건(92.5%)·부정 2,105건(2.5%)이며, 중립 비중이 뚜렷하게 높습니다. 성향 지수는 종합 14.8(중도 균형)입니다.
Facility to support startups, innovators and entrepreneurs with product development, testing and manufacturing infrastructure
The AI boom that has funneled more than $250 billion into OpenAI and Anthropic has left hundreds of startups built before ChatGPT's arrival in 2022 stranded.
Australia has committed $10m to support climate-focused startups in Vietnam, in a move aimed at strengthening the country’s early-stage green investment ecosystem.
President Volodymyr Zelenskyy wants to deepen ties between Ukraine and Silicon Valley's defense tech startups.
AI dominates venture capital research and investments — but the next big startups often break the rules. Human judgment still matters.
Latitude59, an influential startup and technology conference that takes place here annually, is also keen on hosting a networking event in India next year under its aegis
The unlisted shares of Zepto Limited have fallen nearly 30% over the past month despite the company securing regulatory approval for its IPO, highlighting growing caution among investors amid volatile market conditions.Zepto's shares, which were changing hands at around Rs 52 in the unlisted market a month ago, have dropped to about Rs 40, according to dealers tracking pre-IPO transactions.The decline comes even as the quick commerce startup recently received approval from Sebi to launch its much-awaited public issue. The company had taken the confidential route to file the DRHP but may soon file its papers publicly in June, according to Bloomberg.Analysts said the fall reflects weakness in the unlisted market and a broader reassessment of valuations rather than any company-specific development. The company is being valued at around Rs 38,000 crore in the dealer market.Several companies that had planned public offerings this year have either delayed listings or adopted a wait-and-watch approach because of volatility in equity markets, geopolitical tensions and uncertainty around investor demand.The benchmark Nifty has remained under pressure for much of 2026, while foreign institutional investors have continued to remain cautious on Indian equities amid concerns over crude oil prices, global growth and the earnings outlook.The weakness in the secondary market for pre-IPO shares has also affected several startup names, with investors becoming more selective on valuations after a strong rally in the segment over the past two years.Zepto is preparing for a public market debut that could raise around $1.3 billion, or roughly Rs 11,000-12,000 crore, making it one of the largest internet IPOs since the listing of Swiggy.If the issue proceeds as planned, Zepto could become the youngest venture-backed Indian startup to enter public markets, just four years after its founding.The proposed offering is expected to comprise a substantial fresh issue of around Rs 11,000 crore along with an offer-for-sale component by existing investors.The IPO assumes significance because it comes amid intensifying competition in India's fast-growing quick commerce sector.Zepto competes with Blinkit, owned by Eternal, as well as Swiggy Instamart, Flipkart Minutes and Amazon Now.The listing is also expected to strengthen the company's balance sheet at a time when the quick commerce industry continues to spend aggressively on expansion, dark stores and customer acquisition.As of late last year, Zepto had around Rs 7,000 crore in cash, significantly lower than the roughly Rs 17,000-18,000 crore cash reserves reported by listed rivals Eternal and Swiggy.The company raised $450 million in October last year at a valuation of $7 billion. Following the fundraise, it accelerated customer acquisition efforts through higher discounts and promotional campaigns as competition intensified across major cities.Zepto had also completed its domicile shift from Singapore to India, a move increasingly adopted by venture-backed startups preparing for domestic listings.The company has appointed a consortium of investment bankers including Morgan Stanley, HSBC, Goldman Sachs, Axis Capital, JM Financial, IIFL Securities and Motilal Oswal Financial Services to manage the public issue. The IPO is expected to hit the market in the July-September quarter of 2026.While the recent decline in the unlisted share price may reflect near-term market caution, investors will closely watch the final valuation and broader market conditions when Zepto eventually launches what is expected to be one of the year's most closely watched public offerings.(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)
Mill CEO and Nest co-founder Matt Rogers watched Apple render startups obsolete overnight. He says the same dynamic is playing out in AI — and the survival playbook looks familiar.
The internal affairs ministry aims to promote what is known as AI transformation, in which companies reform themselves by placing AI at the center.
The logo of Meta is seen during the Viva Technology conference dedicated to innovation and startups at Porte de Versailles exhibition center in Paris, France, June 12, 2025. — Reuters Meta Platforms plans to start testing an AI pendant in the next year, as it charts a roadmap for...
One of the biggest advances in pancreatic cancer in decades came out of a crazy idea born in a Harvard University lab.Chemical biologist Gregory Verdine believed you could fight disease-causing proteins hidden inside cells by chemically gluing them to something else in the body and smothering them."Everybody told us this is crazy, that it would never work," he recalls.Revolution Medicines, which bought one of Verdine's companies in 2018, recently announced that one of its drugs doubled the typical survival time for patients with aggressive forms of the disease, from 6.7 months to 13.2 months. The full results from the company's final-stage trial are expected to be the star of the show at the annual confab of cancer doctors in Chicago this weekend.Spurred by the success of RevMed, numerous companies are now racing to develop similar drugs, dubbed "molecular glues", which can be used to treat a variety of ailments. And investors and pharmaceutical companies with deep pockets are chasing after them, creating one of the hottest corners of dealmaking in the industry.Also read | India's out-of-pocket healthcare spending drops significantly, govt data showsIt's not unusual for exciting new drugs to spark surges in stock prices and dealmaking frenzy. But molecular glue is a particularly complicated science, and the startups pursuing technologies similar to RevMed are mostly in early stages of testing. Their medicines won't be ready for years, if ever.That hasn't stopped big drugmakers such as Novartis, Roche Holding and Eli Lilly from inking research pacts with glue developers that could pay out billions of dollars in milestones.The boom has been especially lucrative for Monte Rosa Therapeutics. Over the past three years, the Boston-based biotech firm has signed three agreements that could be worth over $10 billion to develop molecular glue drugs with both Novartis and Roche.The company, which trades under the stock ticker GLUE, has seen its shares surge nearly 400% over the past year. It's preparing to start mid-stage trials for multiple drugs by the end of this year."The run-up in the share price is justified based on what we've seen so far," says Robert Driscoll, an analyst at Wedbush. Gains are "due to the success of their drugs rather than kind of exuberance around the glue technology as a whole", he says.Science of GlueMolecular glues work in a fundamentally different way from other oral medicines. Most pills - like Prozac for depression or Lipitor for cholesterol - are tiny chemicals that squeeze into a pocket inside a much larger protein to gum up its functioning. But many proteins have few obvious pockets, including key cancer-causing proteins.In fact, about 80% of all proteins in the body are what scientists refer to as "undruggable", meaning they can't be targeted with traditional drug technologies.RevMed's daraxonrasib cleverly circumvents this problem by acting as a molecular stickum. Once inside the body it binds to a healthy protein on one side and then draws in the bad protein to stick to the other side. The healthy protein helps block the bad protein and turn off its signalling.Competitors Line UpMultiple companies are chasing RevMed's lead in pancreatic cancer despite the long odds. San Diego-based Erasca is in early stages of testing a drug it says is more potent than daraxonrasib. Japanese drugmaker Astellas Pharma has begun final-stage trials of a degrader that may help a subset of pancreatic and lung cancer patients.Molecular glues are also being developed as alternatives to injectable drugs used to treat autoimmune and skin disorders. Shares of Kymera Therapeutics have soared more than 180% in the past year thanks to promising early trial results. The company is developing a once-daily pill it hopes will one day compete with Sanofi and Regeneron Pharmaceuticals' Dupixent, one of the world's bestselling drugs."The technology allows you to go after things that would have been almost impossible" to do previously with pills, says Nello Mainolfi, Kymera's founder and CEO.With few effective options for pancreatic cancer, analysts expect RevMed's daraxonrasib to become an enormous bestseller for the company.Prospects for daraxonrasib and speculation about a potential takeout deal have inflated RevMed's market cap to nearly $33 billion. That's a lofty figure for a drugmaker with no approved medicines.The company is preparing to file for US approval soon, and the FDA has promised to give the drug an ultrafast review. It's projected to reach $7 billion in sales a year by 2032, according to the average of estimates compiled by Bloomberg.
[Leadership] Nigeria's growing influence in Africa's technology and innovation ecosystem has received fresh global recognition as startups founded by Nigerians emerged strongly on Bloomberg's latest list of 25 African Startups to Watch.
PhilDev gala honors startups, innovators carrying the late Filipino tech pioneer Dado Banatao’s legacy
Anthropic raked in $65 billion from investors at a $965 billion valuation in its latest funding round, overtaking OpenAI’s most recent valuation as the two AI startups race to go public. The company announced the additional financing Thursday, with investment firms Altimeter Capital, Dragoneer, Greenoaks and Sequoia Capital leading the round. It marks a massive...
CEO Ariel Katz argues that while AI can replicate workflow SaaS, it can't copy H1’s unique doctor data.
Itajaí já é referência nacional pela força do porto e pela posição estratégica na logística do sul do Brasil. Agora, a cidade dá um passo rumo ao futuro com o Distrito de Inovação, para ser um polo de tecnologia, empreendedorismo e desenvolvimento sustentável. Com esse projeto, a cidade tem planejado a transformação financeira para as próximas décadas. O projeto em fase de planejamento, foi projetado em uma área de 221,8 hectares no bairro Itaipava. No mesmo espaço, o distrito vai integrar indústrias, empresas de tecnologia, startups, universidades, moradias e espaços de convivência. Do total da área, 67% serão destinados à preservação ambiental, para que crescimento e sustentabilidade caminhem juntos. A previsão é de que a novidade integre a região da Associação dos Municípios da Foz do Rio Itajaí-Açu (AMFRI) e impacte toda a economia do Litoral Norte catarinense. Quando pronto, o distrito deve atuar como um ecossistema que conecte empresas, centros de pesquisa e poder público, para gerar empregos qualificados, ampliar oportunidades e elevar a renda regional de forma sustentável e competitiva. Além das indústrias e empresas de tecnologia, o Distrito de Inovação prevê a criação de um bairro planejado com moradias de qualidade, prédios corporativos e espaços de convivência. Um polo farmacêutico entre os maiores do país Um dos destaques do projeto é a instalação de um polo farmacêutico de escala internacional dentro do Distrito de Inovação. Para o prefeito Robison Coelho, o anúncio representa uma virada estratégica para a economia local. “Nós vamos ter no Distrito de Inovação um dos maiores polos farmacêuticos do país. É um segmento em que Itajaí ainda não atuava diretamente como setor produtivo, apenas na importação. É uma área que gera muita receita, muitas divisas e tem um papel estratégico para a soberania nacional ", afirma. Segundo Robison, o município já concluiu todas as etapas de consultas e análises junto aos órgãos de controle e está na fase final para a assinatura do contrato. A expectativa, com o projeto, é a geração de centenas de empregos, especialmente em setores essenciais com as mudanças da Reforma Tributária. Inovação em Itajaí já tem base consolidada O Distrito de Inovação é uma iniciativa que teve como referência o Centro Regional de Inovação Elume, inaugurado em 2023 no município, com investimento superior a R$ 8 milhões. Localizado na área onde será implantado o futuro distrito, o Elume já funciona como um hub de desenvolvimento de negócios inovadores, com infraestrutura tecnológica, serviços compartilhados e suporte especializado para startups, empresas e projetos de pesquisa. Toda a região da AMFRI é atendida no Centro, que conta com universidades como UFSC, IFSC, UDESC e Univali, além do poder público e do setor produtivo. Essa convergência permite que a pesquisa acadêmica se transforme em soluções práticas, e que empresas tenham acesso a conhecimento e tecnologia em escala regional. O distrito amplia esse conceito, já que a proposta contempla diferentes tipologias de espaços produtivos, como lotes industriais, fábricas de design padrão e fábricas de alta tecnologia. Quando pronta, toda a estrutura deve atender desde empresas em estágio inicial até indústrias já consolidadas. Indústria de defesa e logística estratégica Para além da tecnologia, Itajaí também assinou um protocolo de intenções com a Fiesc e o Sebrae para a criação de um polo da indústria de defesa na cidade. O setor já tem uma grande relevância no município, berço do projeto Classe Tamandaré, que envolve a construção de quatro corvetas para a Marinha brasileira. “A meta é expandir essa indústria, abrindo oportunidade para empresas locais ou que se instalarem no município possam vender seus produtos para a Marinha, o Exército e a Aeronáutica, que é um grande mercado para vários equipamentos e insumos” explicou Robison. Um dos fatores que reforçam o potencial do projeto em Itajaí é a vocação logística da cidade. O município conta com porto, universidades, proximidade com aeroportos e, em breve, um dos principais aeroportos executivos do Brasil. Além disso, a malha viária também é estratégica, já que as rodovias BR-101, BR-470, Jorge Lacerda e Antônio Heil conectam Itajaí com o resto do país. A expectativa do prefeito é que Itajaí mantenha, nos próximos anos, um ritmo de crescimento acima das médias estadual e nacional. Segundo ele, a cidade deve continuar o processo de desenvolvimento ao investir e apoiar as iniciativas que já funcionam. — Itajaí vai continuar crescendo e se desenvolvendo em um ritmo muito maior do que a média nacional e estadual, gerando mais empregos e oportunidades. Nós temos um crescimento populacional previsto e precisamos garantir que esse desenvolvimento aconteça de forma equilibrada e sustentável — conclui. Acompanhe todos os conteúdos da série Caminhos do Litoral Norte no site do g1.
Foreign visitors are flocking to China’s factories and AI startups in search of the next technological breakthrough.
Nonprofit investor Elemental Impact will deploy up to $5 million per project in as many as 10 startups through 2027
"There has never been a better time in history to do it; it's the golden age," Anthropic's Boris Cherny said.
Posco has begun recruiting participants for its co-growth smart factory support program for small and medium-sized enterprises as it steps up efforts to strengthen the manufacturing competitiveness of Korean suppliers, the steelmaker announced Wednesday. The program, jointly operated with Korea’s Ministry of SMEs and Startups, supports factory automation and digital transformation for small and mid-sized manufacturers. Since launching the initiative in 2019, Posco said it has invested a cumulati